Prognostic factors for patients treated with abiraterone.

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).

Methods: Retrospective evaluation of patients with mCRPC treated with AA.

Results: 124 patients were identified.